greater
breath
per
minut
infant
younger
month
greater
breath
per
minut
children
month
greater
breath
per
minut
children
year
age
children
symptomat
day
tachypnea
sensit
specif
radiolog
diagnos
pneumonia
studi
sensit
decreas
clinic
sign
includ
tachypnea
addit
clinic
sign
increas
specif
relat
refer
standard
radiolog
diagnos
pneumonia
pneumonia
usual
begin
colon
mucosa
nasopharynx
follow
spread
lower
respiratori
tract
infect
commun
acquir
nosocomi
bacteria
virus
atyp
organ
fungi
known
caus
pneumonia
prospect
research
studi
caus
organ
identifi
nearli
three
quarter
case
pneumonia
respiratori
virus
seem
respons
approxim
case
communityacquir
pneumonia
children
hospit
particularli
year
age
wherea
streptococcu
pneumonia
respons
case
communityacquir
pneumonia
although
infect
mycoplasma
pneumonia
chlamydia
pneumonia
usual
consid
caus
pneumonia
children
school
age
older
patient
one
studi
preschoolag
children
mani
episod
atyp
bacteri
pneumonia
episod
older
children
challeng
view
studi
bacteri
caus
identifi
case
pneumonia
pneumonia
caus
case
bacteri
caus
identifi
bacteri
caus
staphylococcu
aureu
moraxhella
catarrhali
group
streptococci
streptococcu
milleri
haemophilu
speci
nontyp
b
identifi
infrequ
mycoplasma
pneumonia
chlamydia
pneumonia
respons
case
pneumonia
respect
sever
diseas
occur
patient
infect
typic
bacteri
organ
mix
bacteri
usual
pneumonia
viral
coinfect
identifi
bacteri
pneumonia
unlik
wheez
identifi
young
children
level
evid
moder
bacteri
pneumonia
consid
children
fever
higher
c
accompani
tachypnea
recess
although
auscultatori
find
consid
reliabl
clinic
sign
diagnosi
pneumonia
crackl
increas
likelihood
wheez
young
children
preschool
age
suggest
viral
caus
older
subject
increas
possibl
infect
pneumonia
fever
headach
myalgia
older
children
associ
pneumonia
wherea
sticki
eye
neonat
associ
chlamydia
trachomati
infect
histori
import
evalu
communityacquir
pneumonia
physician
inquir
contact
travel
immun
histori
possibl
foreign
bodi
aspir
primari
aspir
stool
consist
malabsorpt
sinus
asthma
environment
exposur
examin
evalu
gener
featur
growth
upper
airway
anatomi
dysmorph
suggest
syndrom
neuromuscular
weak
swallow
gag
reflex
pulmonari
examin
assess
oxygen
satur
respiratori
rate
accessori
muscl
use
wheez
auscultatori
find
crackl
cardiovascular
examin
also
import
rule
sign
cardiac
failur
term
sever
recommend
children
chest
indraw
admit
hospit
british
thorac
societi
guidelin
regard
admiss
hospit
develop
world
shown
box
investig
indic
routin
mild
childhood
pneumonia
optim
durat
treatment
unknown
advoc
treatment
day
level
evid
low
numer
adjunct
therapi
addit
antibiot
prescrib
frequent
treatment
pneumonia
tabl
widespread
variat
practic
regard
investig
pneumonia
children
admit
condit
chest
radiograph
perform
routin
children
suspect
pneumonia
level
evid
high
radiolog
find
accept
refer
standard
defin
pneumonia
clear
extent
chest
radiograph
alter
outcom
childhood
pneumonia
even
though
frequent
use
confirm
presenc
site
extent
pulmonari
infiltr
one
studi
children
month
year
age
recoveri
occur
median
day
whether
chest
radiograph
perform
differ
subsequ
health
care
use
chest
radiograph
significantli
increas
likelihood
prescrib
antibiot
howev
routin
use
chest
radiographi
benefici
ambulatori
children
age
month
acut
lower
respiratori
tract
infect
british
thorac
societi
suggest
chest
radiograph
consid
child
younger
year
fever
higher
c
unknown
origin
without
featur
typic
bronchiol
although
lobar
infiltr
effus
abscess
caviti
chest
radiograph
like
consequ
bacteri
rather
viral
pneumonia
chest
radiograph
chang
specif
differenti
bacteri
viral
pneumonia
therefor
indic
need
treatment
antibiot
blood
cultur
posit
children
pneumonia
pneumonia
bacteremia
occur
studi
gambia
clinic
sign
predict
posit
blood
cultur
high
fever
c
dehydr
nasal
flare
grunt
bronchial
breath
sound
diminish
air
entri
recent
antibiot
use
reduc
chanc
posit
blood
cultur
develop
countri
antibiot
prescrib
earlier
cours
lower
respiratori
ill
clinic
featur
predict
posit
blood
cultur
like
differ
british
thorac
societi
guidelin
recommend
perform
blood
cultur
children
hospit
bacteri
pneumonia
suspect
lung
aspir
consid
peripher
consolid
proven
chest
radiograph
level
evid
moder
pleural
aspir
indic
signific
pleural
effus
identifi
level
evid
moder
microbiolog
investig
gener
recommend
patient
manag
commun
within
hospit
set
older
children
may
abl
provid
sputum
sampl
younger
children
usual
pulmonari
tuberculosi
tb
suspect
consecut
earli
morn
preprandi
preambulatori
gastric
wash
indic
sensit
bronchoalveolar
lavag
induct
sputum
use
hyperton
salin
may
also
use
tb
suspect
techniqu
increas
chanc
typic
noninfecti
patient
render
temporarili
infecti
procedur
hospit
infant
month
age
nasopharyng
aspir
sent
viral
antigen
detect
immunofluoresc
without
viral
cultur
signific
pleural
fluid
present
aspir
sent
microscop
aspir
cultur
earli
possibl
cours
diseas
specimen
save
bacteri
antigen
detect
pleural
fluid
associ
complic
parapneumon
effus
sampl
pleural
fluid
like
obtain
manag
complic
circumst
addit
diagnost
pleural
tap
may
best
interest
child
lung
aspir
rare
perform
techniqu
safer
wide
perceiv
provid
bacteri
diagnosi
case
lung
aspir
therefor
sensit
blood
cultur
organ
identifi
techniqu
frequent
differ
identifi
blood
cultur
taken
children
limit
lung
aspir
pain
result
small
usual
clinic
insignific
pneumothorax
techniqu
usual
limit
pneumonia
associ
dens
peripher
consolid
close
chest
wall
lung
aspir
conjunct
use
nucleic
amplif
test
potenti
increas
yield
therefor
lung
aspir
consid
benefit
identifi
caus
agent
outweigh
modest
risk
procedur
equip
expertis
manag
potenti
complic
pneumothorax
avail
common
organ
caus
pneumonia
neonat
group
b
streptococci
gramneg
enter
bacteria
cytomegaloviru
ureaplasma
urealyticum
listeria
monocytogen
c
trachomati
less
common
organ
caus
pneumonia
neonat
pneumonia
group
streptococcu
anaerob
common
organ
caus
pneumonia
infant
respiratori
syncyti
viru
parainfluenza
virus
influenza
virus
adenoviru
metapneumoviru
pneumonia
h
influenza
pneumonia
mycobacterium
tuberculosi
less
common
organ
caus
pneumonia
infant
bordetella
pertussi
pneumocysti
jiroveci
common
organ
caus
pneumonia
preschoolag
children
respiratori
syncyti
viru
parainfluenza
virus
influenza
virus
adenoviru
metapneumoviru
pneumonia
h
influenza
pneumonia
tuberculosi
less
common
organ
caus
pneumonia
preschoolag
children
c
pneumonia
common
organ
caus
pneumonia
schoolag
children
pneumonia
c
pneumonia
pneumonia
tuberculosi
respiratori
virus
follow
organ
rare
caus
pneumonia
initi
manag
alway
commenc
assess
airway
breath
circul
children
requir
admiss
hospit
children
whose
oxygen
satur
less
air
receiv
supplement
oxygen
therapi
zambian
studi
mortal
pneumonia
increas
hypoxemia
present
find
highlight
import
oxygen
treatment
intraven
fluid
rare
indic
may
requir
presenc
sever
dehydr
ongo
vomit
sever
electrolyt
disturb
respiratori
failur
context
inappropri
secret
antidiuret
hormon
may
occur
intraven
fluid
may
need
administ
full
mainten
children
mild
symptom
requir
treatment
antibiot
level
evid
moder
amoxicillin
coamoxyclavulan
acid
antibiot
choic
preschool
children
level
evid
moder
children
year
age
also
treat
amoxicillin
coamoxyclavulan
acid
macrolid
atyp
infect
suspect
level
evid
moder
antibiot
administ
oral
safe
effect
children
level
evid
high
optim
durat
treatment
child
admit
pneumonia
unknown
recommend
day
antibiot
level
evid
low
decis
made
treat
antibiot
oral
rout
appropri
children
although
cotrimoxazol
wide
use
firstchoic
antibiot
throughout
world
inferior
treatment
amoxicillin
sever
pneumonia
amoxicillin
recommend
first
line
therapi
children
year
rel
inexpens
well
toler
effect
pathogen
age
group
coamoxyclavulan
acid
seem
significantli
effect
oral
amoxicillin
alon
expens
children
older
year
amoxicillin
appropri
firstlin
agent
unless
mycoplasma
chlamydia
pneumonia
suspect
case
macrolid
antibiot
either
alon
addit
appropri
erythromycin
equal
effect
significantli
cheaper
secondgener
macrolid
azithromycin
clarithromycin
roxithromycin
shorter
halflif
requir
frequent
dose
also
may
associ
frequent
advers
effect
especi
involv
gastrointestin
tract
evid
intraven
treatment
superior
oral
treatment
communityacquir
pneumonia
intraven
antibiot
therefor
reserv
sever
case
pneumonia
pneumonia
child
unabl
toler
oral
antibiot
appropri
antibiot
administ
intraven
includ
benzyl
penicillin
coamoxyclavulan
acid
secondor
thirdgener
cephalosporin
addit
macrolid
atyp
infect
consid
possibl
antibiot
resist
common
increas
partli
respons
inappropri
antibiot
prescrib
level
evid
moder
principl
good
antibiot
prescrib
eg
use
appropri
antibiot
narrowest
spectrum
aim
high
tissu
plasma
concentr
shorthalf
life
administ
short
intens
cours
import
less
like
induc
antibiot
resist
resist
antibiot
usual
acquir
select
pressur
bacteria
result
exposur
antibiot
preferenti
surviv
resist
organ
pneumococc
resist
document
isol
high
rate
report
spain
franc
unit
state
mutat
gene
code
penicillinbind
protein
lead
decreas
affin
penicillin
consequ
failur
penicillin
inhibit
enzym
respons
cell
wall
synthesi
pneumococc
resist
penicillin
occur
mean
inhibitori
concentr
less
mgml
evid
treatment
highdos
penicillin
cephalosporin
pneumonia
pneumococc
resist
document
associ
clinic
failur
howev
would
consid
use
thirdgener
cephalosporin
vancomycin
clinic
resist
suspect
resist
identifi
child
immunosuppress
isol
h
influenza
includ
nontyp
strain
resist
ampicillin
product
organ
inhibit
antibiot
therefor
area
high
endem
resist
resist
suspect
clinic
identifi
immunosuppress
individu
treatment
thirdgener
cephalosporin
indic
strain
aureu
penicillin
resist
preval
methicillinflucloxacillin
resist
also
widespread
particularli
hospitalacquir
infect
also
found
communityacquir
infect
vancomycin
teicoplanin
antibiot
choic
treat
infect
least
vancomycin
resist
suspect
outcom
may
better
rifampicin
ad
treatment
vancomycin
benefit
confirm
communityacquir
pneumonia
apart
resist
aureu
bacteria
caus
hospitalacquir
pneumonia
gramneg
organ
pseudomona
speci
serratia
speci
escherichia
coli
enterobact
speci
multidrug
resist
document
bacteria
local
guidelin
necessari
appropri
select
antibiot
vaccin
h
influenza
pneumonia
effect
level
evid
high
vaccin
current
avail
popul
pneumonia
highest
mortal
level
evid
high
recent
develop
introduct
conjug
vaccin
h
influenza
type
b
hib
pneumonia
led
degre
control
pneumonia
caus
two
organ
develop
countri
introduc
immun
schedul
hib
vaccin
introduc
first
report
bacteri
pneumonia
vaccin
trial
develop
world
gambia
hib
vaccin
reduc
clinic
pneumonia
radiolog
pneumonia
lung
aspir
identifi
cultur
posit
hib
children
receiv
vaccin
studi
studi
chile
also
confirm
clinic
efficaci
hib
vaccin
indonesian
studi
howev
coverag
chest
radiograph
much
greater
two
studi
found
evid
reduct
radiolog
pneumonia
result
vaccin
even
though
reduct
clinic
diagnos
lower
respiratori
ill
confirm
first
pneumococc
conjug
vaccin
introduc
studi
unit
state
south
africa
gambia
demonstr
efficaci
develop
clinic
diagnos
pneumonia
sever
pneumonia
radiolog
defin
pneumonia
vaccin
serotypespecif
bacteremia
lung
aspir
cultur
newer
vaccin
incorpor
serotyp
nine
includ
gambian
south
african
studi
like
offer
improv
efficaci
introduc
least
pneumococc
serotyp
howev
risk
serotyp
replac
eventu
result
diminish
benefit
vaccin
optim
schedul
administr
sevenval
pneumococc
vaccin
yet
determin
antibiot
becom
less
effect
common
bacteri
caus
childhood
pneumonia
role
primari
vaccin
becom
increasingli
import
vaccin
decreas
circul
resist
organ
case
pneumonia
current
sevenval
vaccin
effect
serotyp
commonli
associ
antibiot
resist
environment
nutrit
socioeconom
factor
affect
mortal
childhood
pneumonia
prevent
level
evid
high
next
decad
crucial
vaccin
becom
avail
children
develop
world
greatest
risk
die
pneumonia
failur
make
vaccin
avail
would
indic
motiv
behind
vaccin
develop
includ
desir
affect
significantli
global
childhood
mortal
caus
pneumonia
environment
nutrit
socioeconom
factor
affect
equiti
access
crucial
import
also
concert
effort
address
factor
mani
develop
nation
begin
last
centuri
result
larg
reduct
mortal
pneumonia
occur
avail
antibiot
point
mortal
pneumonia
childhood
reflect
socioeconom
disadvantag
factor
estim
nearli
one
fifth
childhood
death
caus
pneumonia
claim
million
live
annual
see
fig
death
occur
africa
southeast
asia
caus
either
communityacquir
pneumonia
infect
secondari
measl
pertussi
aidshiv
death
prevent
avail
intervent
although
episod
result
death
produc
signific
morbid
shortterm
sequela
may
detriment
effect
child
nutrit
statu
also
may
influenc
risk
childhood
diseas
effect
strategi
combat
problem
includ
integr
manag
childhood
ill
imci
program
nutrit
intervent
immun
use
case
manag
guidelin
recommend
imci
childhood
pneumonia
reduc
overal
pneumoniaspecif
mortal
children
significantli
gener
imci
guidelin
meant
target
lead
caus
mortal
sever
morbid
children
year
age
particularli
vulner
age
group
imci
strategi
incorpor
assess
feed
updat
immun
statu
provis
vitamin
prophylaxi
three
compon
imci
program
improv
skill
health
worker
improv
health
system
improv
household
commun
practic
imci
consid
among
costeffect
intervent
lowand
middleincom
countri
program
like
greatest
impact
global
burden
diseas
decemb
countri
around
world
adopt
imci
guidelin
use
oral
cotrimoxazol
rather
oralparenter
antibiot
treatment
nonsever
pneumonia
level
evid
high
use
ambulatori
shortcours
amoxicillin
treatment
sever
pneumonia
level
evid
high
use
parenter
chloramphenicol
instead
ampicillin
plu
gentamicin
sever
pneumonia
level
evid
high
communitybas
intervent
identifi
treat
pneumonia
consider
effect
child
mortal
guidelin
case
manag
acut
respiratori
infect
base
simpl
sign
fast
breath
indraw
chest
design
countri
infant
mortal
rate
higher
per
live
birth
defin
case
suspect
pneumonia
children
report
ill
associ
cough
accompani
fast
andor
difficult
breath
recommend
children
cough
without
fast
breath
treat
outpati
without
antibiot
fast
breath
nonsever
pneumonia
treat
home
oral
cotrimoxazol
amoxicillin
day
lower
chest
indraw
sever
pneumonia
gener
danger
sign
sever
diseas
refer
hospit
treat
parenter
ampicillinpenicillin
recent
metaanalysi
assess
effect
pneumonia
casemanag
approach
mortal
identifi
reduct
total
mortal
reduct
pneumonia
mortal
children
year
age
analysi
nine
studi
conclud
communitybas
intervent
identifi
treat
pneumonia
reduc
child
mortal
consider
consist
result
despit
divers
pneumonia
intervent
developingcountri
set
trial
took
place
potenti
limit
analysi
studi
undertaken
decad
ago
increas
preval
antimicrobi
resist
implic
public
health
program
unclear
last
decad
recent
studi
look
efficaci
variou
antibiot
regimen
develop
countri
set
case
suspect
pneumonia
set
treat
oral
parenter
antibiot
depend
sever
potenti
choic
antibiot
wide
applic
largescal
use
lowresourc
set
cotrimoxazol
cheap
effect
drug
studi
show
compar
favor
antibiot
nonsever
pneumonia
studi
compar
efficaci
cotrimoxazol
amoxicillin
nonsever
pneumonia
examin
associ
vitro
cotrimoxazol
suscept
found
differ
efficaci
cotrimoxazol
amoxicillin
despit
high
vitro
resist
cotrimoxazol
anoth
studi
compar
clinic
efficaci
twicedaili
oral
cotrimoxazol
twicedaili
oral
amoxicillin
found
equal
effect
treatment
nonsever
pneumonia
three
studi
compar
cotrimoxazol
chloramphenicol
procain
penicillin
day
follow
day
oral
ampicillin
intramuscular
procain
penicillin
g
benzathin
penicillin
g
combin
procain
penicillin
g
indic
differ
efficaci
altern
antibiot
regimen
anoth
doubleblind
random
control
trial
compar
cours
standard
dose
mgkgd
oral
amoxicillin
treatment
nonsever
pneumonia
versu
cours
doubl
dose
mgkgd
found
differ
two
dose
studi
assess
oral
treatment
sever
pneumonia
conclud
home
treatment
highdos
oral
amoxicillin
equival
current
recommend
hospit
parenter
ampicillin
treatment
sever
pneumonia
without
underli
complic
recent
cochran
review
suggest
amoxicillin
better
cotrimoxazol
sever
pneumonia
anoth
studi
show
combin
parenter
ampicillin
gentamicin
efficaci
parenter
chloramphenicol
alon
base
find
revis
guidelin
manag
sever
pneumonia
includ
home
treatment
highdos
oral
amoxicillin
combin
parenter
ampicillin
gentamicin
hospit
patient
worsen
tb
pandem
remain
major
threat
global
health
tb
kill
nearli
million
peopl
everi
year
per
day
precis
estim
burden
childhood
tb
readili
avail
primarili
reflect
difficulti
diagnos
tb
accur
children
children
repres
increas
proport
total
number
case
tbendem
area
howev
almost
children
succumb
diseas
year
although
overwhelm
burden
diseas
develop
countri
sever
develop
countri
also
report
recent
increas
number
tb
case
children
although
children
initi
infect
occur
lung
tb
children
adolesc
consid
least
potenti
system
diseas
primari
complex
compris
site
infect
involv
region
lymph
node
may
heal
complic
may
develop
enlarg
ruptur
region
lymph
node
spread
tubercl
bacilli
bloodstream
give
rise
dissemin
diseas
risk
dissemin
greatest
first
year
life
within
first
month
infect
seen
commonli
children
adult
recent
tuberculosi
coalit
technic
assist
partner
publish
intern
standard
care
manag
tb
reader
refer
import
document
standard
relat
diagnosi
treatment
public
health
respons
tb
diagnosi
tb
infect
base
tuberculin
skin
test
tst
absenc
sign
radiolog
find
suggest
tb
diseas
interpret
posit
test
may
modifi
risk
infect
influenc
contact
histori
durat
contact
medic
histori
age
individu
bacil
calmetteguerin
bcg
vaccin
statu
tst
imperfect
test
interpret
subsequ
clinic
manag
depend
prior
probabl
test
posit
clinic
circumst
individu
famili
diagnosi
tb
diseas
base
clinic
symptom
sign
chest
radiograph
investig
smear
cultur
infect
bodi
materi
although
conflict
report
whether
later
chest
radiograph
increas
yield
detect
intrathorac
lymphadenopathi
ct
consid
excel
tool
detect
mediastin
node
ct
howev
requir
volumetr
scan
protocol
perform
routin
associ
high
radiat
dose
even
though
yield
cultur
low
children
microbiolog
confirm
tb
sought
treatment
start
soon
sampl
obtain
patient
unabl
produc
sputum
gastric
aspir
investig
choic
pulmonari
tb
children
level
evid
moder
younger
children
possibl
obtain
sputum
gastric
aspir
collect
consecut
day
ml
gastric
content
aspir
via
nasogastr
tube
earli
morn
child
fast
hour
prefer
child
still
recumb
smear
cultur
perform
aspir
radiolog
evid
focal
diseas
lobar
segment
subsegment
collaps
clinic
evid
bronchial
obstruct
flexibl
fiberopt
bronchoscopi
may
indic
identifi
biopsi
endobronchi
lesion
ideal
bronchoalveolar
lavag
perform
addit
gastric
aspir
otherwis
bronchoscopi
bronchoalveolar
lavag
offer
advantag
gastric
aspir
inhal
nebul
steril
hyperton
salin
via
ultrason
nebul
use
induc
sputum
patient
unabl
expector
sputum
cough
produc
techniqu
may
suffici
forc
aerosol
tubercl
bacilli
infect
health
care
worker
howev
ideal
sputum
induc
area
higheffici
particul
air
filter
qualifi
personnel
wear
appropri
respiratori
protect
sensit
current
avail
interferongamma
releas
assay
diagnosi
cultureconfirm
tb
diseas
children
high
enough
assay
use
alon
rule
tb
studi
interferongamma
releas
assay
tst
yield
equival
result
detect
latent
tb
infect
children
adjust
made
interpret
tst
base
differ
cutoff
evid
suggest
assay
may
less
sensit
tst
children
limit
data
suggest
situat
valu
tst
greatli
reduc
eg
patient
infect
hiv
interferongamma
releas
assay
may
prove
use
use
adjunct
tst
increas
sensit
specif
situat
interferongamma
releas
assay
might
indic
confirm
infect
child
vaccin
bcg
tst
result
borderlin
positiveneg
replac
tst
repeat
test
tst
like
result
booster
phenomenon
tst
test
consid
like
result
blister
larg
pain
respons
eg
patient
strong
reaction
tst
past
child
unabl
unlik
return
hour
read
tst
treatment
children
latent
tb
infect
evid
tb
diseas
indic
two
reason
first
reduc
risk
patient
develop
diseas
year
immedi
acquir
infect
particularli
children
age
year
extrapulmonari
diseas
common
second
reduc
lifelong
risk
develop
tb
diseas
consequ
infect
goal
achiev
use
isoniazid
therapi
minimum
month
although
dose
isoniazid
mgkg
daili
recommend
dose
mgkg
optim
children
elimin
isoniazid
faster
adult
therefor
rel
larger
dose
requir
achiev
compar
serum
concentr
treatment
latent
tb
infect
particularli
import
hlvposit
children
children
corticosteroid
immunosuppress
therapi
contempl
diabet
chronic
diseas
associ
malnutrit
eg
celiac
diseas
treatment
latent
tb
infect
children
adolesc
side
effect
incid
liver
toxic
children
extrem
low
routin
monitor
liver
function
recommend
rifampicincontain
regim
backbon
antituberculosi
treatment
drugsuscept
tuberculosi
level
evid
high
least
month
treatment
recommend
use
three
four
drug
month
continu
phase
month
isoniazid
rifampicin
level
evid
high
children
tb
diseas
usual
treat
daili
therapi
four
drug
isoniazid
rifampicin
pyrazinamid
ethambutol
month
gener
two
drug
isoniazid
rifampicin
month
normal
drug
given
daili
supervis
therapi
given
day
week
sometim
necessari
adher
daili
therapi
consid
poor
shortcours
therapi
month
shown
effect
children
primari
tb
complic
primari
tb
limit
respiratori
tract
childhood
tb
rare
contagi
level
evid
high
children
tb
diseas
usual
small
bacteri
load
children
less
abl
gener
tussiv
forc
need
aerosol
bacilli
children
rare
cavit
diseas
young
children
swallow
rather
expector
sputum
occasion
adolesc
seen
caviti
caus
tb
may
infecti
adher
multidimension
phenomenon
determin
interplay
socioeconom
health
system
diseaserel
patientrel
therapyrel
factor
pragmat
strategi
enhanc
treatment
adher
includ
emphas
import
adher
outset
treatment
child
famili
assign
key
worker
famili
inform
contact
worker
use
profession
interpret
commun
necessari
rather
famili
member
give
inform
potenti
side
effect
child
famili
provid
pill
organ
multidrug
regim
use
combin
antibiot
prepar
avail
toler
provid
written
inform
appropri
languag
maintain
close
liaison
dispens
pharmaci
regard
collect
script
liquid
prepar
readili
avail
preschool
children
provid
easi
access
followup
parenter
benzyl
penicillin
ampicillin
use
combin
gentamicin
level
evid
high
clinic
express
hiv
diseas
children
highli
variabl
hivrel
lower
respiratori
infect
account
pediatr
admiss
case
fatal
rate
much
higher
children
infect
hiv
addit
pneumonia
aureu
p
jiroveci
gramneg
bacteria
cytomegaloviru
import
opportunist
infect
group
children
develop
revis
guidelin
presumpt
treatment
pneumonia
young
children
region
preval
hiv
high
recommend
children
admit
sever
pneumonia
hivendem
area
receiv
benzyl
penicillin
ampicillin
combin
gentamicin
irrespect
age
infant
receiv
highdos
cotrimoxazol
high
preval
p
jiroveci
report
studi
assess
efficaci
treatment
guidelin
sinc
public
studi
conduct
public
guidelin
use
recommend
conclud
children
older
year
guidelin
effect
irrespect
hiv
statu
age
younger
year
howev
guidelin
found
inadequ
nearli
half
infant
respond
therapi
failur
attribut
polymicrobi
diseas
surgic
excis
cyst
conjunct
benzimidazol
recommend
level
evid
moder
exclus
medic
therapi
reserv
patient
poor
candid
surgeri
level
evid
moder
echinococcosi
hydatid
diseas
caus
cystic
larval
stage
tapeworm
echinococcu
liver
common
site
cyst
format
follow
lung
case
pulmonari
diseas
seem
common
children
younger
individu
although
patient
asymptomat
may
expector
content
cyst
develop
symptom
relat
compress
surround
structur
surgic
excis
cyst
treatment
choic
whenev
feasibl
parasit
remov
complet
patient
cure
surgic
option
lung
cyst
includ
lobectomi
wedg
resect
pericystectomi
intact
endocystectomi
capitonnag
medic
therapi
benzimidazol
valuabl
dissemin
diseas
includ
secondari
lung
pleural
hydatidosi
patient
poor
surgic
risk
intraop
spillag
hydatid
fluid
tissu
amebicid
effect
treatment
level
evid
moder
surgic
manag
reserv
patient
advanc
diseas
level
evid
moder
amebiasi
caus
entameba
histolytica
endem
tropic
countri
lung
second
common
extraintestin
site
ameb
liver
abscess
pleuropulmonari
amebiasi
often
consequ
direct
extens
ameb
liver
abscess
manifest
consolid
lung
abscess
pleural
effusionempyema
hepatobronchi
fistula
tissu
amebicid
metronidazol
chloroquin
dehydroemetin
effect
patient
pulmonari
diseas
percutan
pleural
drainag
surgic
decort
role
patient
advanc
diseas
tropic
eosinophilia
cours
diethylcarbamazin
recommend
level
evid
moder
tropic
eosinophilia
syndrom
character
gener
tissu
reaction
pulmonari
manifest
predomin
underli
hypersensit
reaction
filari
parasit
wuchereria
bancrofti
brugia
malayi
result
cough
breathless
wheez
mark
increas
peripher
eosinophilia
eosinophil
pulmonari
infiltr
treatment
cours
diethylcarbamazin
use
chest
drain
intrapleur
fibrinolyt
level
evid
high
use
videoassist
thoracoscop
surgeri
level
evid
high
number
treatment
option
current
avail
empyema
includ
system
antibiot
alon
combin
thoracocentesi
chest
drain
insert
without
intrapleur
fibrinolyt
surgic
techniqu
videoassist
thoracoscop
surgeri
vat
minithoracotomi
standard
thoracotomi
decort
treatment
option
safe
effect
chest
drain
intrapleur
fibrinolyt
particularli
urokinas
vat
shown
effect
primari
approach
treatment
empyema
shorter
durat
hospit
stay
use
consist
outcom
measur
failur
rate
similar
modal
treatment
cost
treatment
intrapleur
urokinas
around
cheaper
vat
expertis
perform
vat
may
univers
avail
intrapleur
urokinas
advoc
firstlin
manag
metaanalysi
compar
result
nonop
primari
oper
therapi
treatment
pediatr
empyema
review
studi
data
aggreg
report
children
treat
nonop
case
studi
children
treat
primari
oper
approach
case
studi
data
analysi
show
primari
oper
therapi
associ
lower
mortal
rate
lower
reintervent
rate
shorter
length
hospit
decreas
time
thoracostomi
tube
shorter
cours
antibiot
therapi
compar
nonop
therapi
limit
analysi
studi
includ
observ
retrospect
case
note
review
observ
data
analysi
show
length
stay
similar
primari
fibrinolyt
therapi
day
thoracotomi
day
vat
day
analysi
also
suggest
current
surgic
option
childhood
empyema
seem
safe
report
mortal
littl
morbid
complet
resolut
diseas
whatev
treatment
pneumatocel
pneumatocel
resolv
without
treatment
level
evid
moder
refractori
case
requir
surgeri
level
evid
moder
pneumatocel
associ
frequent
staphylococc
pneumonia
also
seen
pneumonia
caus
pneumonia
h
influenza
e
coli
klebsiella
usual
produc
addit
symptom
underli
infect
process
regress
spontan
surgic
manag
includ
drainag
resect
decort
requir
refractori
case
symptomat
lung
abscess
resolv
prolong
cours
antibiot
level
evid
moder
abscess
drainag
hasten
recoveri
level
evid
moder
lung
abscess
coexist
necrot
pneumonia
empyema
usual
requir
surgic
drainag
resolv
prolong
cours
antibiot
administ
pneumon
process
last
decad
howev
increas
interest
earli
use
intervent
radiolog
aspir
lung
abscess
without
placement
extern
drain
way
hasten
recoveri
decreas
hospit
stay
surgic
resect
affect
lobe
associ
signific
morbid
rare
advoc
bronchopleur
fistula
pyopneumothorax
bronchopleur
fistula
resolv
continu
drainag
level
evid
moder
surgic
manag
use
protract
case
level
evid
moder
bronchopleur
fistula
associ
necrot
pneumonia
empyema
usual
peripher
resolv
continu
chest
drainag
sometim
howev
slow
resolv
surgic
manag
must
consid
talc
pleurodesi
limit
decort
muscl
flap
around
bronchopleur
fistula
use
success
protract
case
